SIGA Technologies Plans Business Update Call
In an exciting announcement for stakeholders and the public alike, SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a prominent player in the pharmaceutical industry, is set to host a business update webcast and conference call. This event is scheduled for 4:30 P.M. ET on November 6, 2025. It's a wonderful opportunity for audiences to gain insights directly from the company's leadership, including Chief Executive Officer Diem Nguyen and Chief Financial Officer Daniel Luckshire.
Details of the Call
The upcoming call not only promises valuable updates but also interactive participation. Attendees can tune in by accessing a live webcast available on the SIGA website within its Investor Relations section. It is advisable for participants to log in about 5-10 minutes prior to the scheduled start time to ensure a seamless experience.
How to Join the Call
For those looking to engage directly, joining the call is simple. Domestic callers can connect by dialing 1-800-717-1738, while international participants can reach out via +1-646-307-1865. This accessibility ensures that anyone interested can follow along with the updates provided.
Replay Availability
If you miss the call, SIGA has your back! A replay option will be available for two weeks after the event. Simply dial 1-844-512-2921 for domestic access or +1-412-317-6671 for international. Don’t forget to reference Conference ID: 1141989 to listen to the replay.
About SIGA Technologies
SIGA Technologies is not just a pharmaceutical company; it stands as a leader in global health. The firm is dedicated to innovating medicines aimed at treating and preventing infectious diseases, particularly those caused by orthopoxviruses. Their work highlights a commitment to combating severe infections that can emerge from various sources, whether natural, accidental, or intentional.
Flagship Product: TPOXX
At the forefront of SIGA's offering is TPOXX (tecovirimat), an antiviral medication approved in both the U.S. and Canada for smallpox treatment. Furthermore, it has garnered authorization across Europe, the UK, and Japan for managing other significant infections like mpox (monkeypox), cowpox, and complications stemming from the vaccinia virus. This highlights their significant role in safeguarding public health on a global scale.
Commitment to Global Health
SIGA understands the importance of collaboration in enhancing health outcomes. By aligning with government entities and public health organizations, they actively contribute to building a safer and healthier world. Their mission transcends commercial interests, aiming to provide essential countermeasures against pressing global health threats.
Company Contact Information
For more inquiries, interested parties can reach out to Suzanne Harnett for additional information. Suzanne can be contacted at sharnett@siga.com. She will be glad to assist you with your questions.
Frequently Asked Questions
What is the purpose of the business update call by SIGA?
The call aims to provide stakeholders with updates on the company's activities and future plans, benefiting investors and interested audiences.
How can I access the live webcast for the call?
You can access it through the Investor Relations section of the SIGA website approximately 5-10 minutes before the start time.
Is there a replay available after the call?
Yes, a replay will be available for two weeks post-call, accessible via specific phone numbers and using the designated Conference ID.
What is TPOXX?
TPOXX is SIGA's antiviral medication approved for smallpox treatment, with additional authorization for related viral infections in several countries.
How does SIGA contribute to global health?
SIGA collaborates with government and health agencies to develop innovative medicines addressing significant public health challenges.
